Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Class A Common Stock, par value $0.001 per share
-
Shares outstanding
-
21.9M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
13M
-
Shares change
-
+13M
-
Total reported value, excl. options
-
$229M
-
Value change
-
+$229M
-
Number of buys
-
47
-
Price
-
$17.61
Significant Holders of Contineum Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (CTNM) as of Q2 2024
49 filings reported holding CTNM - Contineum Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share as of Q2 2024.
Contineum Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (CTNM) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13M shares
of 21.9M outstanding shares and own 59.55% of the company stock.
Largest 10 shareholders include SUVRETTA CAPITAL MANAGEMENT, LLC (2.05M shares), JOHNSON & JOHNSON (1.98M shares), PERCEPTIVE ADVISORS LLC (1.57M shares), Versant Venture Management, LLC (918K shares), SECTORAL ASSET MANAGEMENT INC (801K shares), HHLR ADVISORS, LTD. (669K shares), FRANKLIN RESOURCES INC (627K shares), Samsara BioCapital, LLC (589K shares), VANGUARD GROUP INC (472K shares), and Altium Capital Management LP (429K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.